Tradestie Institutional Equity Comparison Engine

ABSI vs DMAC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ABSI trades at N/M Forward P/E with -9108.3% operating margin (-19.6% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABSI sits in BREAKDOWN (15th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABSI N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin -9108.3% vs 0.0% ยท YoY -19.6% vs +0.0%
Momentum & Technical Winner DMAC
1Y +192.6% vs +55.3% ยท 52W Pos 53% vs 55%
Options & Structure Winner DMAC
BREAKDOWN (15th %ile IV) vs SURGE (14th %ile IV)
ABSI NASDAQ
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.72
-8.58% 1D
Market Cap $1.6B
1M Return -6.36%
1Y Return +192.61%
Forward P/E N/M
Unified AI Score
41.2 / 100 SELL
Tech 30.0 Fund 51.0 Flow 71.0 Mom 60.0
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABSI +192.61% DMAC +55.26% Spread: +137.35 pp (ABSI Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ABSI Revenue DMAC Revenue ABSI Op. Margin DMAC Op. Margin Margin Edge
FY2018 N/A $0M N/A -1352.2% DMAC
FY2020 $0M N/A -278.3% N/A ABSI
FY2021 $0M N/A -1573.4% N/A ABSI
FY2022 $10M N/A -1857.5% N/A ABSI
FY2023 $10M N/A -2020.2% N/A ABSI
FY2024 $0M N/A -2401.6% N/A ABSI
FY2025 $0M N/A -4297.0% N/A ABSI

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABSI (2) vs DMAC (5)
Institutional Metric ABSI DMAC Criterion Row Winner
Market Capitalization Scale $1.6B $503.1M Larger Scale ABSI
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -19.6% +0.0% Higher Growth DMAC
Operating Margin (TTM) Profitability -9108.3% 0.0% Higher Margin DMAC
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -58.6% -114.6% Higher ROE ABSI
52-Week Range Position Momentum 53% ($2โ€“$13) 55% ($5โ€“$11) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 3.31ฮฒ ยท 126% Vol 1.74ฮฒ ยท 98% Vol Lower Realized Risk DMAC
Unified Institutional Score Composite Signal 41.2 / 100 (SELL) 46.3 / 100 (HOLD) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABSI vs DMAC Buy Guide
ABSI BREAKDOWN
97d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 15th %ile
IV Regime Compressed (<25th %ile)
Live ABSI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABSI nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.